- ISIN
- US22407B1089
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 29, 2022
Highlights
- Market Cap
- $119.79M
- Enterprise Value
- -$50.60B
- EPS (TTM)
- -$396.58
- Total Revenue (TTM)
- $258.83M
- Gross Profit (TTM)
- $12.87M
- EBITDA (TTM)
- -$7.65B
- Year Range
- $3.71 - $7.75
- Target Price
- $17.50
- ROA (TTM)
- -13.56%
- ROE (TTM)
- -14.75%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
COYA Performance Chart
Coya Therapeutics Inc. (COYA) is down 8.8% since the beginning of the year. At $5 per share, COYA is trading 31.7% below its 52-week high of $8.
Loading charts...
Returns By Period
Coya Therapeutics Inc. (COYA) has returned -8.79% so far this year and -3.91% over the past 12 months.
Coya Therapeutics Inc.
- 1D
- 7.52%
- 1M
- 9.98%
- YTD
- -8.79%
- 6M
- -1.31%
- 1Y
- -3.91%
- 3Y*
- 4.09%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
COYA Monthly Returns History
Based on dividend-adjusted daily data since Dec 29, 2022, COYA's average daily return is +0.11%, while the average monthly return is +1.37%. At this rate, an investment would double in approximately 4.2 years.
Historically, 51% of months were positive and 49% were negative. The best month was Feb 2024 with a return of +52.4%, while the worst month was Mar 2026 at -20.6%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.
On a daily basis, COYA closed higher 46% of trading days. The best single day was Dec 1, 2023 with a return of +29.8%, while the worst single day was Oct 29, 2024 at -27.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -19.83% | 6.67% | -20.56% | 7.36% | 13.95% | 9.75% | -8.79% | ||||||
| 2025 | 6.11% | 16.45% | -8.62% | 1.85% | -19.12% | 7.88% | 3.48% | 10.25% | -13.11% | 10.88% | 3.01% | -10.91% | 1.22% |
| 2024 | -20.38% | 52.37% | 10.34% | -8.77% | -15.80% | -20.47% | 13.20% | -12.10% | 6.97% | 12.09% | -9.82% | -12.12% | -22.67% |
| 2023 | -10.20% | -3.94% | -2.79% | 21.31% | -7.27% | -8.95% | -2.21% | -11.31% | 8.78% | 22.92% | 12.92% | 39.02% | 56.39% |
| 2022 | -0.25% | -0.25% |
Benchmark Metrics
Coya Therapeutics Inc. has an annualized alpha of 7.34%, beta of 0.98, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since December 29, 2022.
- This stock participated in 26.72% of S&P 500 Index downside but only 15.50% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 7.34%
- Beta
- 0.98
- R²
- 0.04
- Upside Capture
- 15.50%
- Downside Capture
- 26.72%
Return for Risk
Risk / Return Rank
COYA ranks 40 for risk / return — below 40% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Coya Therapeutics Inc. (COYA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| COYA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.09 | ||
| Sortino ratioReturn per unit of downside risk | -2.36 | ||
| Omega ratioGain probability vs. loss probability | 1.04 | 1.37 | -0.32 |
| Calmar ratioReturn relative to maximum drawdown | -0.08 | 2.78 | -2.86 |
| Martin ratioReturn relative to average drawdown | -0.14 | 12.44 | -12.58 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Coya Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Coya Therapeutics Inc. was 62.90%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current Coya Therapeutics Inc. drawdown is 48.09%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -62.90%Mar 2026 | 1y 5mo | — | 1y 7moOct 2024 - now |
2024 bear market2024 | -52.47%Aug 2024 | 4mo 29d | 2mo 15d | 7mo 14dMar 2024 - Oct 2024 |
2023 bear market2023 | -43.40%Oct 2023 | 4mo 20d | 1mo 28d | 6mo 18dMay 2023 - Dec 2023 |
2024 bear market2024 | -26.35%Jan 2024 | 18d | 29d | 1mo 17dDec 2023 - Feb 2024 |
2023 bear market2023 | -22.62%Apr 2023 | 2mo 24d | 29d | 3mo 23dJan 2023 - May 2023 |
Drawdown Indicators
| COYA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -62.90% | -56.78% | -6.12% |
Max Drawdown (1Y)Largest decline over 1 year | -48.64% | -9.10% | -39.54% |
Max Drawdown (3Y)Largest decline over 3 years | -62.90% | -18.90% | -44.00% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -48.09% | -1.80% | -46.29% |
Average DrawdownAverage peak-to-trough decline | -31.37% | -10.71% | -20.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.66% | 2.03% | +25.63% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Coya Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Coya Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for COYA relative to other companies in the Biotechnology industry. Currently, COYA has a P/S ratio of 0.4. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for COYA in comparison with other companies in the Biotechnology industry. Currently, COYA has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with COYA
Add Coya Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with COYA